Company: TVRD
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001558370-25-011562
Chunk: 4

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1F
Chunk 4
---
 30, 2025 and December 31, 2024, respectively​  —​  85,503​​​​​​​​​Stockholders' Equity (Deficit):​   ​   ​Common stock, $0.001 par value; 150,000,000 shares and 58,251,629 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 9,373,433, and 2,574,767 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively​  9​  2​Additional paid-in capital​  130,579​  1,103​Accumulated other comprehensive loss​​ (13)​​ —​Accumulated deficit​​ (97,648)​  (92,236)​Total stockholders' equity (deficit)​  32,927​  (91,131)​Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)​$ 43,750​$ 35,199​

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​